Leiden, The Netherlands — September 15, 2025 — Leads & Copy — ProteoNic has launched its novel 2G UNic® transposon platform, available for licensing alongside the expansion of 2G UNic compatibility across transposon systems used by biopharma customers. The new 2G UNic transposon platform combines the advantages of ProteoNic’s proven 2G UNic vector technology with a proprietary transposon system to deliver cell lines with superior productivity, stability, and shorter development timelines.
ProteoNic is also expanding its 2G UNic vector technology offering to include application to existing third-party transposon systems, allowing customers to improve established workflows with a premium vector backbone that boosts performance for cell line generation, regardless of the underlying platform.
The new platform will be presented publicly this week at BioProcess International (BPI), part of Biotech Week Boston, highlighting the platform’s ability to deliver meaningful improvements in productivity and development speed for complex biologics. It has demonstrated more than a two-fold increase in titers supporting production levels of up to 10 g/L.
“We are proud to announce the development and launch of our novel 2G UNic transposon platform that takes productivity, flexibility, and ease of use in cell line generation to the next level”, said Frank Pieper, CEO of ProteoNic.
In addition to applications in therapeutic antibody and protein production, ProteoNic’s transposon platform also holds promise for stable producer cell line generation in cell and gene therapy, opening new opportunities for partners across the biopharmaceutical landscape.
The launch follows a series of successful evaluations with industry partners and marks the full commercial availability of both the 2G UNic transposon platform and expanded 2G UNic vector technology capabilities for licensing.
Jonathan Frampton
VP Business Development
E: frampton@proteonic.nl
Source: ProteoNic
